Hosted on MSN10mon
Alcon’s dry eye drug achieves primary endpoints in Phase III trialsSwitzerland-based Alcon’s dry eye disease drug ... and COMET-3 (NCT05360966) trials enrolled more than 930 patients, aged 30 years and older, with dry eye disease. The studies met their primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback